David Maldonado-Perez
Overview
Explore the profile of David Maldonado-Perez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
423
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Watson R, Ye W, Taylor C, Jungkurth E, Cooper R, Tong O, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38663935
We describe three cases of critical acute myositis with myocarditis occurring within 22 days of each other at a single institution, all within 1 month of receiving the initial cycle...
2.
Hamid M, Cespedes P, Jin C, Chen J, Gileadi U, Antoun E, et al.
Nat Immunol
. 2024 Apr;
25(5):834-846.
PMID: 38561495
Cancer remains one of the leading causes of mortality worldwide, leading to increased interest in utilizing immunotherapy strategies for better cancer treatments. In the past decade, CD103 T cells have...
3.
Rao S, Protheroe A, Cerundolo L, Maldonado-Perez D, Browning L, Lamb A, et al.
Int J Mol Sci
. 2023 Aug;
24(16).
PMID: 37628903
Prostate cancer is typically of acinar adenocarcinoma type but can occasionally present as neuroendocrine and/or ductal type carcinoma. These are associated with clinically aggressive disease, and the former often arises...
4.
Wellington D, Yin Z, Abdel-Haq A, Zhang L, Forbester J, Kite K, et al.
Eur J Immunol
. 2020 Oct;
51(3):742-745.
PMID: 33125710
Using a specific antibody, we found that expression of the viral restriction factor IFITM3 differs across cell types within the immune compartment with higher expression in myeloid rather than lymphoid...
5.
Hu Z, Artibani M, Alsaadi A, Wietek N, Morotti M, Shi T, et al.
Cancer Cell
. 2020 Feb;
37(2):226-242.e7.
PMID: 32049047
The inter-differentiation between cell states promotes cancer cell survival under stress and fosters non-genetic heterogeneity (NGH). NGH is, therefore, a surrogate of tumor resilience but its quantification is confounded by...
6.
Hamid M, Colin-York H, Khalid-Alham N, Browne M, Cerundolo L, Chen J, et al.
Cancer Immunol Res
. 2019 Nov;
8(2):203-216.
PMID: 31771983
Enrichment of CD103 tumor-infiltrating T lymphocytes (TIL) is associated with improved outcomes in patients. However, the characteristics of human CD103 cytotoxic CD8 T cells (CTL) and their role in tumor...
7.
Li X, Wang R, Fan P, Yao X, Qin L, Peng Y, et al.
Front Oncol
. 2019 Nov;
9:1066.
PMID: 31709176
Cancer patients often display dysfunctional antitumor T-cell responses. Because noteworthy benefits of immune checkpoint pathway blockade, such as programmed cell death protein 1 (PD-1) inhibitors, have been achieved in multiple...
8.
Hamid M, Wang R, Yao X, Fan P, Li X, Chang X, et al.
Cancer Immunol Res
. 2019 Jun;
7(8):1293-1306.
PMID: 31213473
Immunotherapy treatments with anti-PD-1 boost recovery in less than 30% of treated cancer patients, indicating the complexity of the tumor microenvironment. Expression of HLA-E is linked to poor clinical outcomes...
9.
Robbe P, Popitsch N, Knight S, Antoniou P, Becq J, He M, et al.
Genet Med
. 2018 Feb;
20(10):1196-1205.
PMID: 29388947
Purpose: Fresh-frozen (FF) tissue is the optimal source of DNA for whole-genome sequencing (WGS) of cancer patients. However, it is not always available, limiting the widespread application of WGS in...
10.
Moyes A, Maldonado-Perez D, Gray G, Denison F
Reprod Sci
. 2010 Oct;
18(4):374-82.
PMID: 20962332
Maternal and placental angiogenic abnormalities are a common feature of preeclampsia. The aim of this study was to determine if endothelial cells from women with preeclampsia exhibit different angiogenic responses...